8-K
filed August 3, 2023, 7:59 PM ET
ticker VYGR
CIK 0001640266
earnings
confidence high
sentiment neutral
materiality 0.65
Voyager Q2 net loss $22.2M, launches anti-Aβ gene therapy for Alzheimer's
Voyager Therapeutics, Inc.
2023-Q2 EPS reported
$2.33
revenue$155,333,000
- Q2 2023 collaboration revenue $4.9M (up from $0.7M YoY); net loss $22.2M vs $19.1M YoY.
- Cash, equivalents and marketable securities $272.7M as of June 30, 2023; funding into 2025.
- New vectorized anti-Aβ antibody gene therapy research initiative for Alzheimer's disease launched.
- Executed license agreement with Sangamo for prion disease treatment using TRACER capsid.
- VY-TAU01 anti-tau antibody IND on track for H1 2024; GLP tox studies to start in 2023.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Voyager Therapeutics, Inc. reported the six months ended June 30, 2023 results: revenue $155.3 million, net income Net income was $101.8 million.
- Period
- the six months ended June 30, 2023
- Revenue
- $155.3 million
- Net income
- Net income was $101.8 million
- Result
- reported results
Exact text from the filing
Voyager had collaboration revenue of $155.3 million for the six months ended June 30, 2023 period
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Voyager Therapeutics, Inc. reported the second quarter of 2023 results: revenue $4.9 million, net income Net loss was $22.2 million.
- Period
- the second quarter of 2023
- Revenue
- $4.9 million
- Net income
- Net loss was $22.2 million
- Result
- reported results
Exact text from the filing
Voyager had collaboration revenue of $4.9 million for the second quarter of 2023
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.